Drug Profile

MES 1022

Alternative Names: MES-1022

Latest Information Update: 09 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mesentech
Class Drug conjugates
Mechanism of Action Prostaglandin E EP4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Fracture

Most Recent Events

18 Nov 2024 Mesentech completes a Phase-I clinical trials in Fracture in Netherlands (SC) (CTIS2023-503866-22-00)
26 Sep 2023 Adverse events data from a preclinical study released by Mesentech (Mesentech pipeline, September 2023)
26 Sep 2023 Pharmacodynamics data from a preclinical study released by Mesentech

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com